- Home
- INZY
INZY
Inozyme Pharma Inc.
as 05-17-2024 4:00pm EST
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 284.5M | IPO Year: | 2020 |
| Target Price: | $17.00 | AVG Volume (30 days): | 680.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.69 - $7.79 | Next Earning Date: | 05-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Inozyme Pharma Inc. (INZY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Treco Douglas A | INZY | CEO | Apr 1 '24 | Sell | $6.94 | 7,523 | $52,209.62 | 20,665 | SEC Form 4 |
Latest Inozyme Pharma Inc. News
INZY Breaking Stock News: Dive into INZY Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
GlobeNewswire
12 days ago
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
16 days ago
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
GlobeNewswire
a month ago
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire
2 months ago
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
GlobeNewswire
2 months ago